Loading…
Employees: 275
Size Cerus (CERS) is a United States Health Care company (Medical Specialties) with a market value of $408M, the 2845th largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.02 on 6 Nov 2026.
Performance Over six months the shares fell 22.6%, against -20.2% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 13.7% over the last twelve months (peer median +11.6%); the operating margin is -12.2% (peer median 5.7%).
Valuation It trades at 1.9× enterprise value to sales against a peer median of 5.0× (6th cheapest of 20).
Capital Return on invested capital runs 35.8 points below its cost of capital (12.7% WACC).
Short interest Short interest is 8.2% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $227M | $206M | $180M | $156M | $162M |
| Revenue growth | — | +14% | +15% | -4% | — |
| Gross profit | $117M | $110M | $97.5M | $84.0M | $84.6M |
| EBITDA | -$25.3M | -$34.3M | -$33.3M | -$54.4M | -$55.8M |
| Net income | -$7.31M | -$15.6M | -$20.9M | -$37.5M | -$42.8M |
| Free cash flow | $328,000 | $1.11M | $8.52M | -$47.8M | -$27.6M |
| Capital expenditure | $3.00M | $3.73M | $2.84M | $4.60M | $2.00M |
| Total debt | $75.0M | $96.9M | $98.1M | $96.0M | $87.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CERS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.4% | -15.1% | 10th highest of 21 |
| 6-month return | -22.6% | -20.2% | 9th lowest of 20 |
| Distance from 52-week high | -41.8% | -40.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +13.7% | +11.6% | 9th highest of 20 |
| Operating margin | -12.2% | 5.7% | 7th lowest of 20 |
| EV / Sales | 1.9× | 5.0× | 6th cheapest of 20 |
| ROIC minus cost of capital | -35.8 pp | -4.9 pp | 4th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cerus CERS | United States | $408M | -23% | +14% | -12% | 1.9× | n/a | n/a |
| Beijing Succeeder Technology 688338.SS | China | $408M | -15% | -4% | 31% | 5.4× | 9.8% | +3.4% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $407M | -14% | +3% | -45% | 1.9× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $407M | -20% | +46% | 8% | 4.3× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $406M | -13% | +7% | 11% | 2.0× | -2.5% | -6.0% |
| SEERS 458870.KS | South Korea | $409M | -70% | +425% | 43% | 5.5× | -9.1% | +247.0% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $412M | n/a | +19% | 3% | 1.6× | 23.3% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $417M | +3% | +12% | 6% | 8.1× | 55.5% | +3.8% |
| Taidoc Technology 4736.TW | Taiwan | $395M | 0% | -6% | 18% | 1.9× | -8.0% | -6.6% |
| YD Bio YDES | United States | $423M | -58% | +17% | -883% | 704.2× | n/a | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -16% | 8.0× | n/a | n/a |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -59% | 5.7× | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 1.0× | -18.5% | +15.4% |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -15% | 4.5× | n/a | n/a |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -5% | 1.5× | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 5.0× | 39.0% | +5.2% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -35% | 5.5× | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 6.0× | 20.0% | +4.4% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 5% | 7.8× | n/a | n/a |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 1.4× | -7.6% | +16.9% |